Target of Rapamycin and developmental mTORopathies

The Bordey Lab has been focused on the mammalian Target of Rapamycin, mTOR. mTOR is a converging point in cell signaling, or in other terms an intracellular hub, that receives signals from diverse intracellular routes and extracellular ligands. Importantly, mTOR is dysregulated in many neurological disorders. These disorders referred to as mTORopathies include (but are not limited to) Tuberous Sclerosis Complex (TSC), autism, Alzheimer’s disease, and Schizophrenia. We have focused on TSC. Dr. Angélique Bordey holds the rank of Professor of Neuroscience at the Yale School of Medicine.

Image courtesy of interviewee

Leave a Reply

Your email address will not be published.

×
You have insight(s) remaining for this month. Register for free and view thousands of insights in our archive today. Subscribe for unlimited access.
Copyright © Faculti Media Limited 2022. All rights reserved.
error:

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×